Regional Medical Laboratory
4142 South Mingo Road
Tulsa, OK. 74146-3632

MEMORANDUM

TO: St. John Medical Center Medical Staff
Regional Medical Laboratory Clients
FROM: Brent D. Hartsell, MD, Laboratory Director, St. John Medical Center
Kendra Thompson, Laboratory Manager, St. John Medical Center
DATE: May 3, 2017

SUBJECT: New Testing Offered: Verify Now – Platelet Function Assay

Regional Medical Laboratory (RML) is pleased to introduce the Verify Now system for testing of platelet responsiveness to a variety of antiplatelet medications. Studies show that up to 1 in 3 patients may not respond adequately to their antiplatelet medications. Patients who do not respond adequately to their antiplatelet medications may be at significantly higher risk of heart attack, stroke, or other potentially life-threatening cardiovascular events.

Verify Now measures patient responsiveness to aspirin or P2Y12 inhibitor drugs (e.g., clopidogrel, ticagrelor, prasugrel) using a citrated whole blood sample. Testing is useful for determining patient responsiveness to antiplatelet drug treatment or to determine the residual effects of antiplatelet therapy prior to surgery or other therapeutic or diagnostic intervention.

The **VerifyNow PRU Test (CPT 85576)** is designed to measure P2Y12 receptor blockade. Results of the PRU Tests are reported as P2Y12 Reaction Units (PRU). **PRU** measures the extent of platelet aggregation in the presence of a P2Y12 inhibitor Lower PRU levels are associated with expected antiplatelet effect.

<180 PRU – suggests P2Y12 inhibitor effect
180-376 PRU – suggests lack of P2Y12 inhibitor effect

The **VerifyNow Aspirin (CPT 85576)** Test is a qualitative test to aid in the detection of platelet dysfunction. The test is reported in Aspirin Reaction Units (ARU).

350-549 ARU – therapeutic range for platelet function.
550-700 ARU – non-therapeutic range for platelet function.

Testing is performed on blood collected in a 2 mL Greiner Bio-One partial fill sodium citrate tube with 3.2% sodium citrate which **cannot be refrigerated or sent to the laboratory via pneumatic tube system.** Testing is ideally performed within 4 hours of specimen collection. Patients should not be tested within 48 hours of the administration of eptifibatide (Integrilin®) or tirofiban (Aggrastat®) or 14 days following the administration of abciximab (ReoPro®).

These tests will be available on May 1, 2017, at the St John Medical Center clinical laboratory and may be ordered using order names **PRU P2Y12 VerifyNow Test** and **Aspirin VerifyNow Test**. Testing will be available for St. John Medical Center and for patients sent from physician offices for testing. Because of the special testing requirements, outpatients should present to the 5th floor draw site in the Siegfried Tower at 1923 S Utica, Monday through Friday, 8 AM - 8 PM, for specimen collection. Please contact Brent Hartsell, MD, Kendra Thompson, or David Belanger at 918.744.2500 at x15529 or x16254 should you have any questions.